Engineered Nanoparticles for Precise Targeted Drug Delivery and Enhanced Therapeutic Efficacy in Cancer Immunotherapy

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2024 Sep 2

PMID 39220871

Authors

Xueqiang Peng

Jianjun Fang

Chuyuan Lou

Liang Yang

Shaobo Shan

Zixian Wang

Yutong Chen

Hangyu Li

Xuexin Li

Affiliations

Soon will be listed here.

Abstract

The advent of cancer immunotherapy has imparted a transformative impact on cancer treatment paradigms by harnessing the power of the immune system. However, the challenge of practical and precise targeting of malignant cells persists. To address this, engineered nanoparticles (NPs) have emerged as a promising solution for enhancing targeted drug delivery in immunotherapeutic interventions, owing to their small size, low immunogenicity, and ease of surface modification. This comprehensive review delves into contemporary research at the nexus of NP engineering and immunotherapy, encompassing an extensive spectrum of NP morphologies and strategies tailored toward optimizing tumor targeting and augmenting therapeutic effectiveness. Moreover, it underscores the mechanisms that NPs leverage to bypass the numerous obstacles encountered in immunotherapeutic regimens and probes into the combined potential of NPs when co-administered with both established and novel immunotherapeutic modalities. Finally, the review evaluates the existing limitations of NPs as drug delivery platforms in immunotherapy, which could shape the path for future advancements in this promising field.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

Calcium Sulfide Nanoclusters Trigger DNA Damage and Induce Cell Cycle Arrest in Non-Small-Cell Lung Adenocarcinoma Cells.

Figueroa Rosado M, Munoz Forti K, Rodriguez-Rodriguez P, Arroyo-Martinez G, Rodriguez-Irizarry V, Ruiz-Rivera A Int J Mol Sci. 2025; 26(4).

PMID: 40004132 PMC: 11855498. DOI: 10.3390/ijms26041665.

Improving systemic delivery of oncolytic virus by cellular carriers.

Peng Z, Kalim M, Lu Y Cancer Biol Med. 2025; 21(12).

PMID: 39831754 PMC: 11745088. DOI: 10.20892/j.issn.2095-3941.2024.0390.

Improving the Anti-Tumor Effect of Indoleamine 2,3-Dioxygenase Inhibitor CY1-4 by CY1-4 Nano-Skeleton Drug Delivery System.

Li H, Liu J, Wang J, Li Z, Yu J, Huang X J Funct Biomater. 2024; 15(12).

PMID: 39728172 PMC: 11676189. DOI: 10.3390/jfb15120372.

References

Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

Dai Y, Xu C, Sun X, Chen X . Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 2017; 46(12):3830-3852. PMC: 5521825. DOI: 10.1039/c6cs00592f. View

Castano A, Demidova T, Hamblin M . Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther. 2014; 2(2):91-106. PMC: 4108218. DOI: 10.1016/S1572-1000(05)00060-8. View

Liu H, Xu P . Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. Adv Drug Deliv Rev. 2022; 191:114619. PMC: 9724744. DOI: 10.1016/j.addr.2022.114619. View

Marega R, Prasetyanto E, Michiels C, De Cola L, Bonifazi D . Fast Targeting and Cancer Cell Uptake of Luminescent Antibody-Nanozeolite Bioconjugates. Small. 2016; 12(39):5431-5441. DOI: 10.1002/smll.201601447. View

Sosnik A, Menaker Raskin M . Polymeric micelles in mucosal drug delivery: Challenges towards clinical translation. Biotechnol Adv. 2015; 33(6 Pt 3):1380-92. DOI: 10.1016/j.biotechadv.2015.01.003. View

Barberio A, Smith S, Pires I, Iyer S, Reinhardt F, Melo M . Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors. Bioeng Transl Med. 2023; 8(2):e10453. PMC: 10013828. DOI: 10.1002/btm2.10453. View

Jneid B, Bochnakian A, Hoffmann C, Delisle F, Djacoto E, Sirven P . Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci Immunol. 2023; 8(79):eabn6612. DOI: 10.1126/sciimmunol.abn6612. View

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q . Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2020; 268:120546. DOI: 10.1016/j.biomaterials.2020.120546. View

10.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

11.

Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

12.

Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

13.

Vogt K, Summers C, Chilvers E, Condliffe A . Priming and de-priming of neutrophil responses in vitro and in vivo. Eur J Clin Invest. 2018; 48 Suppl 2:e12967. DOI: 10.1111/eci.12967. View

14.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

15.

Li J, Lu W, Yang Y, Xiang R, Ling Y, Yu C . Hybrid Nanomaterials for Cancer Immunotherapy. Adv Sci (Weinh). 2022; 10(6):e2204932. PMC: 9951325. DOI: 10.1002/advs.202204932. View

16.

Vangijzegem T, Stanicki D, Laurent S . Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv. 2018; 16(1):69-78. DOI: 10.1080/17425247.2019.1554647. View

17.

Daldrup-Link H, Golovko D, Ruffell B, DeNardo D, Castaneda R, Ansari C . MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res. 2011; 17(17):5695-704. PMC: 3166957. DOI: 10.1158/1078-0432.CCR-10-3420. View

18.

Xiao K, Li Y, Luo J, Lee J, Xiao W, Gonik A . The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011; 32(13):3435-46. PMC: 3055170. DOI: 10.1016/j.biomaterials.2011.01.021. View

19.

Farkas M, Aanei I, Behrens C, Tong G, Murphy S, ONeil J . PET Imaging and biodistribution of chemically modified bacteriophage MS2. Mol Pharm. 2012; 10(1):69-76. DOI: 10.1021/mp3003754. View

20.

Eetezadi S, Ekdawi S, Allen C . The challenges facing block copolymer micelles for cancer therapy: In vivo barriers and clinical translation. Adv Drug Deliv Rev. 2014; 91:7-22. DOI: 10.1016/j.addr.2014.10.001. View